Saturday, July 11, 2026

Drug profile · INN

oxaprozin potassium

oxaprozin potassium (DAYPRO ALTA) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — oxaprozin potassium
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

oxaprozin potassium (DAYPRO ALTA) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN oxaprozin potassium
Brand DAYPRO ALTA
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Route ORAL
Formulation TABLET

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Cyclooxygenase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aspirin Cyclooxygenase inhibitor
  2. bromfenac sodium Cyclooxygenase inhibitor
  3. diclofenac potassium Cyclooxygenase inhibitor
  4. diclofenac sodium Cyclooxygenase inhibitor
  5. diflunisal Nervous system (N02)
  6. fenoprofen calcium Cyclooxygenase inhibitor

Frequently asked questions

What is oxaprozin potassium?

oxaprozin potassium (DAYPRO ALTA) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for oxaprozin potassium?

DAYPRO ALTA is a marketed brand name for oxaprozin potassium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of oxaprozin potassium?

oxaprozin potassium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.